LT3403654T - Geriamosios kortikosteroido kompozicijos - Google Patents

Geriamosios kortikosteroido kompozicijos

Info

Publication number
LT3403654T
LT3403654T LTEP18178891.0T LT18178891T LT3403654T LT 3403654 T LT3403654 T LT 3403654T LT 18178891 T LT18178891 T LT 18178891T LT 3403654 T LT3403654 T LT 3403654T
Authority
LT
Lithuania
Prior art keywords
corticosteroid
organic compositions
compositions
organic
Prior art date
Application number
LTEP18178891.0T
Other languages
English (en)
Inventor
Stephen Perrett
Fredric Jay Cohen
Gopi M. Venkatesh
Original Assignee
Adare Development I, L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43823361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3403654(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adare Development I, L.P. filed Critical Adare Development I, L.P.
Publication of LT3403654T publication Critical patent/LT3403654T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Steroid Compounds (AREA)
LTEP18178891.0T 2009-10-01 2010-09-30 Geriamosios kortikosteroido kompozicijos LT3403654T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24764209P 2009-10-01 2009-10-01

Publications (1)

Publication Number Publication Date
LT3403654T true LT3403654T (lt) 2019-09-10

Family

ID=43823361

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18178891.0T LT3403654T (lt) 2009-10-01 2010-09-30 Geriamosios kortikosteroido kompozicijos
LTEP10821232.5T LT2482822T (lt) 2009-10-01 2010-09-30 Geriamosios kortikosteroidų kompozicijos

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP10821232.5T LT2482822T (lt) 2009-10-01 2010-09-30 Geriamosios kortikosteroidų kompozicijos

Country Status (37)

Country Link
US (9) US8771729B2 (lt)
EP (4) EP2482822B1 (lt)
JP (7) JP2013506683A (lt)
KR (3) KR20120104975A (lt)
CN (3) CN106421797A (lt)
AR (1) AR078499A1 (lt)
AU (1) AU2010300550B2 (lt)
BR (2) BR112012007110A2 (lt)
CA (3) CA3037273C (lt)
CL (1) CL2012000794A1 (lt)
CO (1) CO6531427A2 (lt)
CY (1) CY1122713T1 (lt)
DE (1) DE202010018594U1 (lt)
DK (2) DK3403654T3 (lt)
EA (2) EA024084B1 (lt)
ES (2) ES2683864T3 (lt)
GE (1) GEP20156281B (lt)
HR (2) HRP20181266T1 (lt)
HU (2) HUE046748T2 (lt)
IL (2) IL218928A (lt)
LT (2) LT3403654T (lt)
ME (1) ME03471B (lt)
MX (5) MX390734B (lt)
MY (1) MY171317A (lt)
NZ (2) NZ599401A (lt)
PL (2) PL2482822T3 (lt)
PT (2) PT3403654T (lt)
PY (1) PY1041126A (lt)
RS (2) RS59241B1 (lt)
SG (3) SG10201704847WA (lt)
SI (2) SI2482822T1 (lt)
SM (2) SMT201900468T1 (lt)
TW (2) TWI562779B (lt)
UA (2) UA118087C2 (lt)
UY (1) UY32925A (lt)
WO (1) WO2011041509A1 (lt)
ZA (2) ZA201202208B (lt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CA2765033C (en) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CN106421797A (zh) 2009-10-01 2017-02-22 艾戴尔医药公司 口服给予的皮质类固醇组合物
WO2011163614A2 (en) * 2010-06-24 2011-12-29 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
WO2012020279A1 (en) * 2010-08-13 2012-02-16 Compagnie Gervais Danone Product for the upper gastric sphere
PT3517541T (pt) 2012-05-08 2020-08-28 Nicox Ophthalmics Inc Forma polimórfica de propionato de fluticasona
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2014228990B2 (en) 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
US10716802B2 (en) 2013-03-15 2020-07-21 The Brigham And Women's Hospital, Inc. Compounds to modulate intestinal absorption of nutrients
GB201308933D0 (en) * 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
US9078853B2 (en) 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
WO2015034678A2 (en) * 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2015152517A1 (ko) * 2014-03-31 2015-10-08 (주)세하바이오 항산화 물질 활성 보호를 위한 프롤라민 기반 경구용 필름 제조방법
US9980975B2 (en) 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
EP3047846A1 (en) 2015-01-22 2016-07-27 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US9867834B2 (en) 2015-06-15 2018-01-16 Banner Life Sciences Llc Non-systemic topical compositions comprising corticosteroids
WO2016205172A1 (en) 2015-06-15 2016-12-22 Banner Life Sciences Llc Soft lozenges comprising corticosteroids
WO2017053970A1 (en) 2015-09-24 2017-03-30 The Brigham And Women's Hospital, Inc. Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients
CN105412123B (zh) * 2015-11-06 2018-03-13 山东省千佛山医院 布地奈德联合三唑类抗真菌药物的应用及其产品
ES2992002T3 (es) 2016-04-06 2024-12-05 Astellas Pharma Inc Moldeo tridimensional de elución rápida, filamento para moldeo tridimensional de elución rápida y material para moldeo tridimensional de elución rápida
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
CN107595765A (zh) 2017-09-22 2018-01-19 沈阳兴齐眼药股份有限公司 一种眼用缓释药物递送系统及其制备方法
WO2019157453A1 (en) * 2018-02-12 2019-08-15 Trilogy Therapeutics, Inc. Caspofungin compositions for inhalation
SI25373A (sl) 2018-05-08 2018-08-31 Danijela Marković Naravna orodisperzibilna tableta
WO2020084530A1 (en) 2018-10-24 2020-04-30 Ferring B.V. Mucoadhesive pharmaceutical compositions of corticosteroids
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
WO2021067585A1 (en) * 2019-10-01 2021-04-08 Adare Pharmaceuticals Us, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
KR102275997B1 (ko) * 2019-11-07 2021-07-13 연세대학교 산학협력단 숙주지향치료를 위한 조성물
JP7720226B2 (ja) * 2020-11-09 2025-08-07 東和薬品株式会社 リバーロキサバン含有口腔内崩壊錠
CN114146089B (zh) * 2021-12-15 2023-06-16 安徽贝克生物制药有限公司 含依非韦伦、替诺福韦和恩曲他滨的药物组合物
JP2025526506A (ja) * 2022-07-28 2025-08-13 ザ メディカル カレッジ オブ ウィスコンシン インク 逆流症の治療のための持続放出経口ホスアンプレナビル製剤
US11904046B1 (en) * 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations
CN116869927B (zh) * 2023-09-06 2023-11-10 中国医学科学院北京协和医院 一种用于治疗嗜酸性食管炎的食道温敏凝胶

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1170188A (en) 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
SE378109B (lt) 1972-05-19 1975-08-18 Bofors Ab
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US4080448A (en) 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
CA1201114A (en) * 1980-02-15 1986-02-25 Gordon H. Phillipps Androstane carbothioates
SE8004580L (sv) 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
ATE8790T1 (de) 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
GB8630913D0 (en) 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
ZA892859B (en) 1988-04-22 1989-12-27 Advanced Polymer Systems Inc Porous particles in preparations involving immiscible phases
US5278175A (en) 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
CA2101773A1 (en) 1991-01-31 1992-08-01 Toyoichi Tanaka Interpenetrating-polymer network phase-transition gels
US5252337A (en) 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
DE69424181T2 (de) 1993-12-20 2000-10-19 Minnesota Mining And Mfg. Co., Saint Paul Flunisolide aerosolformulierungen
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9517062D0 (en) 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5863910A (en) 1996-01-12 1999-01-26 Bolonick; Joel Treatment of chronic inflammatory disorders of the gastrointestinal tract
DE19606151C2 (de) 1996-02-20 1999-05-12 Losan Pharma Gmbh Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
DE69733476T2 (de) * 1996-06-14 2006-03-23 Kyowa Hakko Kogyo Co., Ltd. Im munde schnellzerfallende tablette
AU722289B2 (en) 1996-10-01 2000-07-27 Aptalis Pharmatech, Inc. Taste-masked microcapsule compositions and methods of manufacture
SE9604486D0 (sv) 1996-12-05 1996-12-05 Astra Ab Novel formulation
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
IT1291362B1 (it) 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
RO118174B1 (ro) 1997-08-21 2003-03-28 Aventis Pharma Deutschland Gmbh Lac de unghii şi utilizarea acestuia
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
ATE219658T1 (de) 1998-03-06 2002-07-15 Eurand Int Schnell zerfallende tablette
SE514128C2 (sv) 1998-03-17 2001-01-08 Pharmalink Ab Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit
FR2781156B1 (fr) 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6863378B2 (en) 1998-10-16 2005-03-08 Silverbrook Research Pty Ltd Inkjet printer having enclosed actuators
GB9901819D0 (en) 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
CA2370565C (en) 1999-04-23 2008-11-25 Leo Pharma A/S Dermally applicable vitamin d-containing pharmaceutical compositions
GB9915319D0 (en) 1999-06-30 1999-09-01 Unilever Plc Hair treatment compositions
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
AU3221401A (en) 1999-11-30 2001-06-12 Rajesh Jain Fast dissolving composition with prolonged sweet taste
WO2002002081A1 (en) 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
JP2004522802A (ja) 2001-02-16 2004-07-29 ラヴィファーム・ラボラトリーズ・インク 水溶性で風味良い複合体
US20030050312A1 (en) 2001-03-12 2003-03-13 Hjorth Thyge Borup Novel tablets and capsules and a process for its preparation
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US6872405B2 (en) 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
AU2002255321B2 (en) * 2001-05-10 2007-05-17 Astellas Pharma Inc. Tablets quickly disintegrating in the oral cavity and process for producing the same
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US20030206978A1 (en) 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
JP4173670B2 (ja) * 2002-03-08 2008-10-29 旭化成ファーマ株式会社 口腔内崩壊製剤
AU2003230823A1 (en) 2002-04-05 2003-10-27 United States Of America As Represented By The Administrator Of The National Aeronautics And Space Polyimides from 2,3,3',4'-biphenyltetracarboxylic dianhydride and aromatic diamines
ES2298510T3 (es) * 2002-05-03 2008-05-16 Janssen Pharmaceutica Nv Microemulsiones polimericas.
WO2004006481A2 (en) 2002-07-10 2004-01-15 I/O Controls Corporation Fiber optic control network and related method
WO2004021997A2 (en) * 2002-09-06 2004-03-18 Microbia, Inc. Inhibitors of fungal invasion
US20040053902A1 (en) 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4475233B2 (ja) * 2003-01-21 2010-06-09 日本新薬株式会社 口腔内速崩性錠剤
JP2006516616A (ja) * 2003-01-31 2006-07-06 オレクソ・アクチエボラゲット 即効薬剤組成物
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20050009848A1 (en) * 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
US20060134054A1 (en) 2003-12-19 2006-06-22 Council Of Scientific And Industrial Research Polymer composition for pH dependent dissolution behavior and process for preparation thereof
KR20060130723A (ko) 2004-03-10 2006-12-19 쉐링 악티엔게젤샤프트 분자 분산된 드로스피레논을 포함하는 조성물
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
EP1634586B1 (en) 2004-09-09 2007-02-14 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. Fast water-dispersible domperidone tablets
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2007028247A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2007158225A (ja) 2005-12-08 2007-06-21 Canon Inc 露光装置
CN1985799B (zh) * 2005-12-19 2011-11-09 量子高科（北京）研究院有限公司 口腔崩解制剂的制备方法
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP1958613A1 (en) 2007-02-15 2008-08-20 Polichem S.A. Dermal film-forming liquid formulations for drug release to skin
CA2721133C (en) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
US20090131386A1 (en) * 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20150231156A1 (en) 2007-11-13 2015-08-20 Meritage Pharma, Inc. Corticosteroid compositions
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20100216754A1 (en) 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
BRPI0820997A2 (pt) * 2007-12-10 2014-12-23 Eurand Inc Comprimidos de desintegração oral compreendendo difenidramina.
CN101925349A (zh) 2007-12-21 2010-12-22 欧兰德股份有限公司 替马西泮的口腔崩解片组合物
JP2009173552A (ja) * 2008-01-21 2009-08-06 Lion Corp 胃腸薬
SE533435C2 (sv) 2008-04-03 2010-09-28 Hm Power Ab Vridmomentsöverförande arrangemang vid ett vindkraftverk
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
PT2151235E (pt) 2008-07-21 2011-03-21 Falk Pharma Gmbh Formulação farmacêutica para o tratamento do trato digestivo superior
AU2009279521A1 (en) 2008-08-08 2010-02-11 Mcneil-Ppc, Inc. Use of sucralose as a granulating agent
CA2734763C (en) 2008-08-20 2016-06-28 Ranjan Dohil Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
BRPI0924069A2 (pt) 2009-01-15 2017-03-28 Nestec Sa métodos de diagnosticar e tratar disfagia
CA2753444A1 (en) 2009-02-23 2010-08-26 Gopi Venkatesh Controlled-release compositions comprising a proton pump inhibitor
CA2765033C (en) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
AU2010291171B2 (en) 2009-09-07 2015-10-29 Dbv Technologies Method of treating eosinophilic esophagitis
CN106421797A (zh) 2009-10-01 2017-02-22 艾戴尔医药公司 口服给予的皮质类固醇组合物
BR112012012999A2 (pt) 2009-11-30 2019-04-02 Aptalis Pharmatech Inc Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt)
WO2011163614A2 (en) 2010-06-24 2011-12-29 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
CN108969490A (zh) 2010-12-02 2018-12-11 艾戴尔医药公司 快速分散颗粒、口腔崩解片以及方法
BR112013018168A2 (pt) 2011-01-18 2018-09-25 University Health Network método e dispositivo para detecção de distúrbio de deglutição
US10238331B2 (en) 2011-01-28 2019-03-26 Nestec S.A. Apparatuses and methods for diagnosing swallowing dysfunction
JP2015522653A (ja) 2012-07-26 2015-08-06 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ プロトンポンプ阻害剤の医薬組成物
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
PL2886108T5 (pl) 2013-12-23 2023-02-27 Dr. Falk Pharma Gmbh Zoptymalizowana formulacja farmaceutyczna do leczenia zmian zapalnych przełyku
WO2015142739A1 (en) 2014-03-17 2015-09-24 Children's Hospital Medical Center Genetic test for determining susceptibility for eosinophilic esophagitis
US10176301B2 (en) 2014-09-11 2019-01-08 Meritage Pharma, Inc. Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis
US9980975B2 (en) 2015-01-22 2018-05-29 Ems S.A. Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus
US10869592B2 (en) 2015-02-23 2020-12-22 Uroviu Corp. Handheld surgical endoscope
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI777515B (zh) * 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2019165138A1 (en) 2018-02-21 2019-08-29 Adare Development I, L.P. Methods of managing eosinophilic esophagitis
WO2021067585A1 (en) 2019-10-01 2021-04-08 Adare Pharmaceuticals Us, L.P. Methods of treating eosinophilic esophagitis and reducing candidiasis
WO2022020464A1 (en) 2020-07-21 2022-01-27 Ellodi Pharmaceuticals, L.P. Modified release rapidly disintegrating compositions of proton pump inhibitors
IL307637A (en) 2021-04-20 2023-12-01 Ellodi Pharmaceuticals L P Methods for treating esophageal strictures

Also Published As

Publication number Publication date
EP3760187A1 (en) 2021-01-06
JP6249935B2 (ja) 2017-12-20
EP2482822A1 (en) 2012-08-08
CA3037273A1 (en) 2011-04-07
EA031157B9 (ru) 2019-01-31
EP2482822A4 (en) 2014-03-12
US11246828B2 (en) 2022-02-15
EA024084B1 (ru) 2016-08-31
EP3403654A1 (en) 2018-11-21
CN107252488A (zh) 2017-10-17
MX2019005289A (es) 2019-08-05
KR20140088236A (ko) 2014-07-09
GEP20156281B (en) 2015-05-11
KR20120104975A (ko) 2012-09-24
AU2010300550B2 (en) 2014-10-30
PY1041126A (es) 2015-10-01
EP3403654B1 (en) 2019-07-31
KR20150043548A (ko) 2015-04-22
CA3037273C (en) 2022-05-03
TWI562779B (en) 2016-12-21
BR112012007110A2 (pt) 2021-08-31
SG10201405886WA (en) 2014-11-27
AU2010300550A1 (en) 2012-04-12
EA201491358A1 (ru) 2015-03-31
PL2482822T3 (pl) 2018-10-31
CL2012000794A1 (es) 2012-07-20
DK3403654T3 (da) 2019-08-26
RS57595B1 (sr) 2018-11-30
MX364947B (es) 2019-05-15
CA2776164A1 (en) 2011-04-07
CN106421797A (zh) 2017-02-22
US9849084B2 (en) 2017-12-26
HRP20191435T1 (hr) 2019-11-15
ES2683864T3 (es) 2018-09-28
US20210244660A1 (en) 2021-08-12
IL218928A (en) 2016-10-31
US12290598B2 (en) 2025-05-06
JP2023166486A (ja) 2023-11-21
DE202010018594U1 (de) 2018-02-16
PT2482822T (pt) 2018-10-04
JP2015096540A (ja) 2015-05-21
US20170071855A1 (en) 2017-03-16
CA2776164C (en) 2016-12-13
US20200214979A1 (en) 2020-07-09
SG10201912526TA (en) 2020-02-27
IL238915A (en) 2017-06-29
ZA201202208B (en) 2014-11-26
EA031157B1 (ru) 2018-11-30
ES2742525T3 (es) 2020-02-14
MX2022003132A (es) 2022-05-16
UY32925A (es) 2011-04-29
NZ624922A (en) 2016-05-27
US20220339098A1 (en) 2022-10-27
MY171317A (en) 2019-10-08
NZ599401A (en) 2014-09-26
HRP20181266T1 (hr) 2018-10-05
JP2013506683A (ja) 2013-02-28
AR078499A1 (es) 2011-11-09
US10632069B2 (en) 2020-04-28
BR122022005637B1 (pt) 2023-03-07
EP2482822B1 (en) 2018-08-01
JP2022078275A (ja) 2022-05-24
US20140287051A1 (en) 2014-09-25
SMT201900468T1 (it) 2019-09-09
SI2482822T1 (sl) 2018-10-30
MX380787B (es) 2025-03-11
EP2845595A1 (en) 2015-03-11
TW201117815A (en) 2011-06-01
US20260021041A1 (en) 2026-01-22
MX2020007226A (es) 2020-10-12
US20140303131A1 (en) 2014-10-09
US9387167B2 (en) 2016-07-12
IL238915A0 (en) 2015-06-30
TW201521732A (zh) 2015-06-16
MX390734B (es) 2025-03-21
JP7042015B2 (ja) 2022-03-25
PT3403654T (pt) 2019-09-05
HUE046748T2 (hu) 2020-03-30
ZA201301380B (en) 2014-07-30
US9486407B2 (en) 2016-11-08
UA108360C2 (uk) 2015-04-27
US20110081411A1 (en) 2011-04-07
UA118087C2 (uk) 2018-11-26
CN102665722A (zh) 2012-09-12
DK2482822T3 (en) 2018-08-27
SG10201704847WA (en) 2017-07-28
US11266598B2 (en) 2022-03-08
HUE040119T2 (hu) 2019-02-28
WO2011041509A1 (en) 2011-04-07
JP2017036306A (ja) 2017-02-16
CO6531427A2 (es) 2012-09-28
EA201290171A1 (ru) 2012-11-30
JP2018100286A (ja) 2018-06-28
CY1122713T1 (el) 2021-03-12
LT2482822T (lt) 2018-09-10
US8771729B2 (en) 2014-07-08
SMT201800427T1 (it) 2018-09-13
TWI594754B (zh) 2017-08-11
SI3403654T1 (sl) 2019-10-30
PL3403654T3 (pl) 2019-11-29
CA2940931A1 (en) 2011-04-07
RS59241B1 (sr) 2019-10-31
MX2012003823A (es) 2012-07-30
ME03471B (me) 2020-01-20
IL218928A0 (en) 2012-07-31
JP6293230B2 (ja) 2018-03-14
CA2940931C (en) 2019-04-30
JP2020097625A (ja) 2020-06-25
US20180153802A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
LT3403654T (lt) Geriamosios kortikosteroido kompozicijos
BRPI1007025A2 (pt) composições esteroidais
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
EP2488022A4 (en) Compositions
UY33161A (es) Composiciones plaguicidas
DOP2011000396A (es) Composiciones novedosas
SMT201600307B (it) Composizione liposomiale
DK2640893T4 (da) Sammensætninger
EP2470605A4 (en) Cured polyhydroxyalkanoate compositions
LT3246021T (lt) Apiksabano kompozicijos
PL2214679T3 (pl) Kompozycje kortykosteroidów
BRPI1013588A2 (pt) composição
BRPI1012539A2 (pt) composições farmacêuticas
BRPI1010690A2 (pt) composições
BRPI1011587A2 (pt) compostos e composições terapèuticas
BRPI1015474A2 (pt) composição
LT3158991T (lt) Bendamustino kompozicijos
UY33155A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
IT1394400B1 (it) Composizioni farmaceutiche
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
FI20095644A0 (fi) Ulokkeen muodostaminen
EP2624836A4 (en) BEPOTASTIN COMPOSITION
DK2453858T3 (da) Fremgangsmåde
EP2563347A4 (en) TRANSDERMAL PROPYNYLAMINOINDANE COMPOSITIONS